Ocugen, Inc. (OCGN)Healthcare | Biotechnology | Malvern, United States | NasdaqCM
0.89 USD
-0.06
(-6.524%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 9 a.m. EDT
Ocugen presents a classic 'value trap' scenario where aggressive analyst upgrades and a 'strong buy' recommendation clash violently with deteriorating reality. The company is burning cash at an alarming rate, with operating cash flow draining at nearly $61 million annually and free cash flow in the millions of losses. The balance sheet is fragile, with debt exceeding cash reserves and a current ratio below 1.0, leaving little room for error in a biotech sector that demands perfection. Despite a recent price uptick, the underlying business is structurally broken, evidenced by nine consecutive years of cumulative price destruction and a lack of sustainable profitability. The options market confirms this skepticism, with traders aggressively buying insurance against further drops rather than betting on a recovery. While the catalysts mentioned in headlines regarding clinical milestones are critical, the financial runway is precarious, making this a high-risk speculative play rather than a sound investment. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.090144 |
| AutoETS | 0.090145 |
| AutoTheta | 0.090191 |
| MSTL | 0.098822 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 7.23 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.022 |
| Excess Kurtosis | -0.27 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.014 |
| Market Cap | 300,248,352 |
| Forward P/E | -3.50 |
| Beta | 2.27 |
| Website | https://www.ocugen.com |
As of Oct. 10, 2026, 9 a.m. EDT: Speculators are heavily positioned for downside protection, with massive open interest in out-of-the-money puts relative to calls. The put/call ratio is skewed significantly toward bearish bets, particularly for the January 2027 expiration where deep out-of-the-money puts dominate volume. While there is some call activity at strikes above the current price, the overwhelming capital allocation suggests a fear of further decline rather than a bet on a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.4329341 |
| Address1 | 11 Great Valley Parkway |
| All Time High | 778.2 |
| All Time Low | 0.17 |
| Ask | 1.02 |
| Ask Size | 1 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 6,800,720 |
| Average Daily Volume3 Month | 6,045,004 |
| Average Volume | 6,045,004 |
| Average Volume10Days | 6,800,720 |
| Beta | 2.268 |
| Bid | 0.7684 |
| Bid Size | 1 |
| Board Risk | 8 |
| Book Value | -0.049 |
| City | Malvern |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.8854 |
| Current Ratio | 0.802 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 0.9454 |
| Day Low | 0.87 |
| Display Name | Ocugen |
| Dividend Date | 1,569,801,600 |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,019,400 |
| Earnings Call Timestamp Start | 1,786,019,400 |
| Earnings Timestamp | 1,786,019,400 |
| Earnings Timestamp End | 1,793,881,800 |
| Earnings Timestamp Start | 1,793,881,800 |
| Ebitda | -67,173,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -4.29 |
| Enterprise To Revenue | 62.908 |
| Enterprise Value | 288,183,360 |
| Eps Current Year | -0.23667 |
| Eps Forward | -0.25333 |
| Eps Trailing Twelve Months | -0.26 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.18934 |
| Fifty Day Average Change | -0.30394 |
| Fifty Day Average Change Percent | -0.2555535 |
| Fifty Two Week Change Percent | -43.29341 |
| Fifty Two Week High | 2.725 |
| Fifty Two Week High Change | -1.8395998 |
| Fifty Two Week High Change Percent | -0.67508256 |
| Fifty Two Week Low | 0.87 |
| Fifty Two Week Low Change | 0.0153999925 |
| Fifty Two Week Low Change Percent | 0.017701142 |
| Fifty Two Week Range | 0.87 - 2.725 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,417,617,000,000 |
| Float Shares | 333,776,194 |
| Forward Eps | -0.25333 |
| Forward P E | -3.4950461 |
| Free Cashflow | -1,974,375 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 116 |
| Fullday Change | -0.046599984 |
| Fullday Change Percent | -4.9197617 |
| Fullday Price | 0.8854 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Gross Profits | -39,182,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.015420001 |
| Held Percent Institutions | 0.43575 |
| Implied Shares Outstanding | 339,110,401 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,569,801,600 |
| Last Split Factor | 1:60 |
| Long Business Summary | Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania. |
| Long Name | Ocugen, Inc. |
| Market | us_market |
| Market Cap | 300,248,352 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_303874231 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -81,811,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 423,152,320 |
| Number Of Analyst Opinions | 6 |
| Open | 0.9454 |
| Operating Cashflow | -60,869,000 |
| Operating Margins | -11.051081 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 484 328 4701 |
| Previous Close | 0.9472 |
| Price Eps Current Year | -3.741074 |
| Price Hint | 4 |
| Price To Book | -18.069387 |
| Price To Sales Trailing12 Months | 65.5421 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.752 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.16667 |
| Region | US |
| Regular Market Change | -0.0618 |
| Regular Market Change Percent | -6.52449 |
| Regular Market Day High | 0.9454 |
| Regular Market Day Low | 0.87 |
| Regular Market Day Range | 0.87 - 0.9454 |
| Regular Market Open | 0.9454 |
| Regular Market Previous Close | 0.9472 |
| Regular Market Price | 0.8854 |
| Regular Market Time | 1,791,921,600 |
| Regular Market Volume | 6,859,539 |
| Return On Assets | -0.48441002 |
| Revenue Growth | 0.084 |
| Revenue Per Share | 0.014 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 339,110,401 |
| Shares Percent Shares Out | 0.3009 |
| Shares Short | 102,053,118 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 98,309,421 |
| Short Name | Ocugen, Inc. |
| Short Percent Of Float | 0.3009 |
| Short Ratio | 11.75 |
| Source Interval | 15 |
| State | PA |
| Symbol | OCGN |
| Target High Price | 22.0 |
| Target Low Price | 8.0 |
| Target Mean Price | 12.16667 |
| Target Median Price | 10.5 |
| Total Cash | 100,051,000 |
| Total Cash Per Share | 0.295 |
| Total Debt | 87,986,000 |
| Total Revenue | 4,581,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.26 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.48116 |
| Two Hundred Day Average Change | -0.59576005 |
| Two Hundred Day Average Change Percent | -0.40222532 |
| Type Disp | Equity |
| Volume | 6,859,539 |
| Website | https://www.ocugen.com |
| Zip | 19,355 |